169 related articles for article (PubMed ID: 38648061)
1. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
3. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A
JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
Grönberg H; Eklund M; Picker W; Aly M; Jäderling F; Adolfsson J; Landquist M; Haug ES; Ström P; Carlsson S; Nordström T
Eur Urol; 2018 Dec; 74(6):722-728. PubMed ID: 30001824
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.
Hao S; Heintz E; Östensson E; Discacciati A; Jäderling F; Grönberg H; Eklund M; Nordström T; Clements MS
Eur Urol; 2022 Jul; 82(1):12-19. PubMed ID: 35094896
[TBL] [Abstract][Full Text] [Related]
6. Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI.
Nordström T; Jäderling F; Carlsson S; Aly M; Grönberg H; Eklund M
BMJ Open; 2019 Jun; 9(6):e027816. PubMed ID: 31201191
[TBL] [Abstract][Full Text] [Related]
7. Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy.
Nordström T; Adolfsson J; Grönberg H; Eklund M
BMC Urol; 2017 Oct; 17(1):92. PubMed ID: 28974201
[TBL] [Abstract][Full Text] [Related]
8. A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging.
Palsdottir T; Nordström T; Aly M; Jäderling F; Clements M; Grönberg H; Eklund M
Eur Urol Oncol; 2019 Sep; 2(5):490-496. PubMed ID: 31412016
[TBL] [Abstract][Full Text] [Related]
9. External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
Palsdottir T; Grönberg H; Hilmisson A; Eklund M; Nordström T; Vigneswaran HT
Eur Urol Focus; 2023 May; 9(3):455-462. PubMed ID: 36522257
[TBL] [Abstract][Full Text] [Related]
10. Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test.
Vigneswaran HT; Palsdottir T; Olsson H; Haug ES; Picker W; Löffeler S; Grönberg H; Eklund M; Nordström T
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):457-464. PubMed ID: 33168965
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
[TBL] [Abstract][Full Text] [Related]
12. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study.
Eldred-Evans D; Burak P; Connor MJ; Day E; Evans M; Fiorentino F; Gammon M; Hosking-Jervis F; Klimowska-Nassar N; McGuire W; Padhani AR; Prevost AT; Price D; Sokhi H; Tam H; Winkler M; Ahmed HU
JAMA Oncol; 2021 Mar; 7(3):395-402. PubMed ID: 33570542
[TBL] [Abstract][Full Text] [Related]
13. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
Auvinen A; Tammela TLJ; Mirtti T; Lilja H; Tolonen T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Natunen K; Nevalainen J; Raitanen J; Ronkainen J; van der Kwast T; Riikonen J; Pétas A; Matikainen M; Taari K; Kilpeläinen T; Rannikko AS;
JAMA; 2024 May; 331(17):1452-1459. PubMed ID: 38581254
[TBL] [Abstract][Full Text] [Related]
14. A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study.
Waldén M; Aldrimer M; Lagerlöf JH; Eklund M; Grönberg H; Nordström T; Palsdottir T
Eur Urol Open Sci; 2022 Apr; 38():32-39. PubMed ID: 35495282
[TBL] [Abstract][Full Text] [Related]
15. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
16. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
[TBL] [Abstract][Full Text] [Related]
17. The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.
Möller A; Olsson H; Grönberg H; Eklund M; Aly M; Nordström T
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):137-142. PubMed ID: 30171228
[TBL] [Abstract][Full Text] [Related]
18. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
[TBL] [Abstract][Full Text] [Related]
19. MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.
Eklund M; Jäderling F; Discacciati A; Bergman M; Annerstedt M; Aly M; Glaessgen A; Carlsson S; Grönberg H; Nordström T;
N Engl J Med; 2021 Sep; 385(10):908-920. PubMed ID: 34237810
[TBL] [Abstract][Full Text] [Related]
20. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience.
Viste E; Vinje CA; Lid TG; Skeie S; Evjen-Olsen Ø; Nordström T; Thorsen O; Gilje B; Janssen EAM; Kjosavik SR
Scand J Prim Health Care; 2020 Sep; 38(3):315-322. PubMed ID: 32772613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]